Related Experiment Videos
Moxalactam therapy of Haemophilus influenzae type b meningitis in children
Abstract:
Thirty-four children with Haemophilus influenzae type b meningitis were given prospectively either moxalactam (200 mg/kg/day) or ampicillin (400 mg/kg/day) plus chloramphenicol (75 mg/kg/day). One patient in each group died. The mean duration of fever, clinical response, sequential cerebrospinal fluid findings, and incidence of neurologic sequelae were similar between groups. Moxalactam cerebrospinal fluid bioactivity was significantly greater than that of ampicillin or chloramphenicol throughout therapy. Neutropenia, liver enzyme abnormalities, and diarrhea were not significantly different. In eight of 11 patients given moxalactam (versus one of 14 controls) there was complete elimination of gram-negative aerobic flora in the stools by day 10 (P = 0.002); however, none acquired Clostridium difficile. Moxalactam in effective therapy for H. influenzae type b meningitis.
Insights
Moxalactam and ampicillin plus chloramphenicol showed similar outcomes for Haemophilus influenzae type b meningitis in children. Moxalactam demonstrated superior cerebrospinal fluid bioactivity and reduced gut flora without increased side effects.
Area of Science:
- Pediatric Infectious Diseases
- Bacteriology
- Pharmacology
Background:
- Haemophilus influenzae type b meningitis remains a significant pediatric health concern.
- Antibiotic therapy is crucial for managing H. influenzae type b meningitis.
- Comparing novel antibiotics with established regimens is essential for optimizing treatment.
Purpose of the Study:
- To compare the efficacy and safety of moxalactam versus ampicillin plus chloramphenicol in treating pediatric H. influenzae type b meningitis.
- To evaluate cerebrospinal fluid (CSF) bioactivity and impact on gut flora.
- To assess clinical outcomes and neurologic sequelae.
Main Methods:
- Prospective study of 34 children with H. influenzae type b meningitis.
- Treatment groups: moxalactam or ampicillin plus chloramphenicol.
- Evaluation of clinical response, fever duration, CSF parameters, neurologic sequelae, and adverse events.
Main Results:
- No significant differences in mortality, fever duration, clinical response, or neurologic sequelae between groups.
- Moxalactam exhibited significantly greater CSF bioactivity compared to ampicillin or chloramphenicol.
- Moxalactam led to complete elimination of gram-negative aerobic stool flora in 8/11 patients without C. difficile.
Conclusions:
- Moxalactam is an effective therapeutic option for H. influenzae type b meningitis.
- Moxalactam offers improved CSF penetration and favorable effects on gut microbiota.
- The safety profile of moxalactam was comparable to the control group.